Retatrutide Phase 3 Results: What the Data Actually Means

About this episode

The episode discusses the results of the retatrutide phase 3 trial and its implications for weight loss and cardiometabolic health.

Dr. Spencer Nadolsky and Karl sit down with David W, a nurse practitioner who was actually enrolled in the Triumph 1 retatrutide phase 3 trial, to break down data just presented at the American Diabetes Association conference showing average weight loss of up to 30 percent and cardiometabolic benefits that go well beyond anything tirzepatide or semaglutide produce on their own. David went from 240 pounds to 167 in the trial and walks through exactly what the experience felt like from the inside while Spencer and Karl explain what the numbers mean for patients and clinicians waiting for this drug to reach the market.

People in this episode

Hosts: Dr. Spencer Nadolsky, Karl

Guest: David W

Topics covered

• weight loss
• diabetes
• clinical trials
• cardiometabolic health
• medication
• patient experience

Keywords

• retatrutide
• weight loss
• diabetes
• clinical trial
• cardiometabolic benefits
• American Diabetes Association
• tirzepatide
• semaglutide

Mentioned in this episode

Organizations: American Diabetes Association

Products: retatrutide, tirzepatide, semaglutide

More episodes of Docs Who Lift

• GLP-1 Maintenance: What Happens When You Lower Your Dose, Switch Medications, or Stop Entirely · May 25, 2026 · 40 min
• Are GLP-1 Medicines Shredding Your Bones? Here Is What the Actual Evidence Says With Dr. Susan Brian · May 18, 2026 · 32 min
• Heavy Metal Toxicity: Separating Real Risks From Influencer Scams | Dr. Eryn Russo · May 5, 2026 · 53 min
• GLP-1 Genetics: Predicting Weight Loss and Side Effects With 23andMe's Dr. Adam Auton · April 21, 2026 · 25 min
• Do GLP-1 Medicines Actually Cause Muscle Loss? New Research With Dr. Henning Langer · April 14, 2026 · 36 min
• How Often Should You Really Lift Weights? Feat. Dr. Stuart Phillips · April 2, 2026 · 52 min